Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

606 Articles

Chris Lange | Aug 12, 2015 at 9:45 AM EDT

Short Sellers Back Off Big Pharma

The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical…

Jon C. Ogg | Aug 10, 2015 at 3:19 PM EDT

Why AbbVie Should Be Worth 25% More

Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.

Chris Lange | Jul 27, 2015 at 8:21 AM EDT

Short Sellers Run For Cover From Major Pharma

ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a…

Chris Lange | Jul 24, 2015 at 9:10 AM EDT

Are AbbVie Earnings Enough?

AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.

Chris Lange | Jul 23, 2015 at 1:25 PM EDT

What to Expect From AbbVie Earnings

Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.

Paul Ausick | Jul 20, 2015 at 9:35 AM EDT

Top Health Care Earnings for the Week Ahead

Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been…

Lee Jackson | Jul 14, 2015 at 10:20 AM EDT

3 Top Big Pharmaceutical Stocks With Upcoming Catalysts

A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for…

Chris Lange | Jul 13, 2015 at 8:05 AM EDT

Short Sellers Run for Cover in Big Pharma

The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short…

Lee Jackson | Jul 8, 2015 at 8:55 AM EDT

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay…

Chris Lange | Jun 26, 2015 at 11:35 AM EDT

Is Big Pharma Advertising Getting Out of Control?

How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?

Chris Lange | Jun 25, 2015 at 8:10 AM EDT

Short Sellers Become More Focused on Big Pharma

The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short…

Lee Jackson | Jun 15, 2015 at 9:15 AM EDT

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price…

Chris Lange | Jun 10, 2015 at 8:30 AM EDT

Short Sellers Back Off Big Pharma

The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Trey Thoelcke | Jun 10, 2015 at 6:49 AM EDT

The 6 Most Shorted NYSE Stocks in May

AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15…

Chris Lange | Jun 8, 2015 at 1:00 PM EDT

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical…

1 … 34 35 36 37 38 … 41

AbbVie : ABBV

All AbbVie Articles

Short Sellers Back Off Big Pharma

Why AbbVie Should Be Worth 25% More

Short Sellers Run For Cover From Major Pharma

Are AbbVie Earnings Enough?

What to Expect From AbbVie Earnings

Top Health Care Earnings for the Week Ahead

3 Top Big Pharmaceutical Stocks With Upcoming Catalysts

Short Sellers Run for Cover in Big Pharma

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

Is Big Pharma Advertising Getting Out of Control?

Short Sellers Become More Focused on Big Pharma

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

Short Sellers Back Off Big Pharma

The 6 Most Shorted NYSE Stocks in May

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

‘The Borrower Is Slave to the Lender’: Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

'The Borrower Is Slave to the Lender': Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

$1 Million in Retirement Savings Spends Like $40,000 a Year. Here's Why That's Not Enough.

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

AbbVie : ABBV

All AbbVie Articles

Short Sellers Back Off Big Pharma

Why AbbVie Should Be Worth 25% More

Short Sellers Run For Cover From Major Pharma

Are AbbVie Earnings Enough?

What to Expect From AbbVie Earnings

Top Health Care Earnings for the Week Ahead

3 Top Big Pharmaceutical Stocks With Upcoming Catalysts

Short Sellers Run for Cover in Big Pharma

3 UBS Must-Own Large-Cap Pharmaceutical Stocks

Is Big Pharma Advertising Getting Out of Control?

Short Sellers Become More Focused on Big Pharma

Jefferies Franchise Stock Picks Crush S&P 500: 4 to Buy Now

Short Sellers Back Off Big Pharma

The 6 Most Shorted NYSE Stocks in May

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

AI XRP Price Prediction: Claude Fable 5 Predicts the XRP Price for End of 2026

The Monthly Income Trap: How JEPQ Investors Gave Up $18,000 Per $10,000 Invested Since Inception

‘The Borrower Is Slave to the Lender’: Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

Featured Reads

'The Borrower Is Slave to the Lender': Dave Ramsey Warns a 22-Year-Old Against Letting a Rich Friend Pay Off His $70,000 Debt

$1 Million in Retirement Savings Spends Like $40,000 a Year. Here's Why That's Not Enough.